CPHI Webinar: Early multi-functional approach is the best way to incorporate patient centricity into drug formulations
The concept of patient centricity has many nuances, and designing dosage forms needs to be underpinned by a multi-functional perspective utilised as early as possible, say experts
Designing effective patient-centric dosage forms needs to be underpinned by a practical multi-functional view which considers all the angles, according to a panel of experts speaking at a recent CPHI Webinar, available here on-demand.
In the Webinar Defining and Designing Patient-Centric Dosage Forms sponsored by SPI Pharma and chaired by Leanne West, Principal Research Scientist & Chief Engineer of Paediatric Technologies, Georgia Tech, the implications of designing drugs that tick all the boxes for patient centricity were discussed both from a commercial and academic perspective.
Dr Graeme Macleod, Global Research & Development Manager, SPI Pharma said it was important to take a multi-functional view on what is meant by patient centricity: “What does your target patient group look like, what is the disease, is the disease chronic or acute, where is the patient actually receiving the medicine, and are they in a particular group where it’s difficult to take the medication?”
He added that from a pharmaceutical development point of view, it was essential to get as much information as early in the development process as possible and not lose sight of certain commercial considerations such as ascertaining what technologies are available inhouse and the cost of development.
“From a formulation perspective, you’ve really got to think about not only designing the right dosage form, but also about what you can achieve practically,” he said. “In general, it’s about having a dose form that is safe and efficacious and trying to make it designed to be as patient centric as possible within the certain limitations we have.”
Nielsen Hobbs, Executive Editor, Policy and Regulation, Pink Sheet said the more formulation developers hold discussions with patients and take a “blue sky approach” to what is possible, “the easier their development could end up being.”
Hannah Batchelor, Professor, Strathclyde Institute of Pharmacy and Biomedical Sciences said patient centricity should be considered as early as possible in the drug development process.
She gave the example of a project for an oral product for rheumatoid arthritis in which developers did look from the very beginning at issues such as the size and shape of the tablet for easier handling and grip as patients may have dexterity issues.
“It is looked at relatively early; in development pipeline terms, it’s probably just prior to Phase I is where I’ve seen patient centricity considered previously,” she added.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance